Skip Navigation

Cardiovascular Research 2007 74(1):11-18; doi:10.1016/j.cardiores.2006.10.009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hopkins, T. A.
Right arrow Articles by Walsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hopkins, T. A.
Right arrow Articles by Walsh, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Adiponectin actions in the cardiovascular system

Teresa A. Hopkins, Noriyuki Ouchi, Rei Shibata and Kenneth Walsh*

Molecular Cardiology/Whitaker Cardiovascular Institute, Boston University School of Medicine, 715 Albany Street, W611, Boston, MA 02118, USA

* Corresponding author. Tel.: +1 617 414 2390; fax: +1 617 414 2391. Email address: kxwalsh{at}bu.edu

Obesity is strongly associated with the pathogenesis of type 2 diabetes, hypertension, and cardiovascular disease. Levels of the hormone adiponectin are downregulated in obese individuals, and several experimental studies show that adiponectin protects against the development of various obesity-related metabolic and cardiovascular diseases. Adiponectin exhibits favorable effects on atherogenesis, endothelial function, and vascular remodeling by modulation of signaling cascades in cells of the vasculature. More recent findings have shown that adiponectin directly affects signaling in cardiac cells and is beneficial in the setting of pathological cardiac remodeling and acute cardiac injury. Several of these effects of adiponectin have been attributed to the activation of the 5' AMP-activated protein kinase signaling cascade and other signaling proteins. This review will discuss the epidemiological and experimental studies that have elucidated the role of adiponectin in a variety of cardiovascular diseases.

KEYWORDS Diabetes; Epidemiology; Heart failure; Remodeling; Protein kinases

Time for primary review 22 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
Eur. Heart J., September 5, 2008; (2008) ehn387v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. R. Kizer, J. I. Barzilay, L. H. Kuller, and J. S. Gottdiener
Adiponectin and Risk of Coronary Heart Disease in Older Men and Women
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3357 - 3364.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. J. Peterson, G. Drummond, D. H. Kim, M. Li, A. L. Kruger, S. Ikehara, and N. G. Abraham
L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice
J. Lipid Res., August 1, 2008; 49(8): 1658 - 1669.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. Harmancey, C. R. Wilson, and H. Taegtmeyer
Adaptation and Maladaptation of the Heart in Obesity
Hypertension, August 1, 2008; 52(2): 181 - 187.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. H. Kim, A. P. Burgess, M. Li, P. L. Tsenovoy, F. Addabbo, J. A. McClung, N. Puri, and N. G. Abraham
Heme Oxygenase-Mediated Increases in Adiponectin Decrease Fat Content and Inflammatory Cytokines Tumor Necrosis Factor-{alpha} and Interleukin-6 in Zucker Rats and Reduce Adipogenesis in Human Mesenchymal Stem Cells
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 833 - 840.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Li, D. H. Kim, P. L. Tsenovoy, S. J. Peterson, R. Rezzani, L. F. Rodella, W. S. Aronow, S. Ikehara, and N. G. Abraham
Treatment of Obese Diabetic Mice With a Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance
Diabetes, June 1, 2008; 57(6): 1526 - 1535.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S.-Q. Xu, K. Mahadev, X. Wu, L. Fuchsel, S. Donnelly, R. G. Scalia, and B. J. Goldstein
Adiponectin Protects Against Angiotensin II or Tumor Necrosis Factor {alpha}-Induced Endothelial Cell Monolayer Hyperpermeability: Role of cAMP/PKA Signaling
Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 899 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. T. Gonon, U. Widegren, A. Bulhak, F. Salehzadeh, J. Persson, P.-O. Sjoquist, and J. Pernow
Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide
Cardiovasc Res, April 1, 2008; 78(1): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. G. Abraham and A. Kappas
Pharmacological and Clinical Aspects of Heme Oxygenase
Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.